Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsBusiness Wire • 04/29/24
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine salesCNBC • 04/25/24
Merck's first-quarter results beat expectations amid healthy vaccine-sales growthMarket Watch • 04/25/24
Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds PersistInvestors Business Daily • 04/25/24
Merck (MRK) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 04/18/24